Abstract
Objectives: Recognizing bipolar disorder as a multi-system metabolic condition driven, in part, by binge eating behavior and atypical depressive symptoms, this study aimed to quantify diet quality and evaluate clinical correlates in a bipolar disorder cohort. Methods: Participants from the Mayo Clinic Bipolar Disorder Biobank (n = 734) completed the Rapid Eating Assessment for Participants – Shortened version (REAP-S) to determine diet quality. The average REAP-S score for a U.S. omnivorous diet is 32 (range 13 to 39) with higher scores indicating healthier diet. Demographic variables were collected in a standardized clinical questionnaire. Depressive symptoms were assessed by the Bipolar Inventory of Symptoms Scale. Cardiometabolic variables were retrieved from the electronic health record. Associations between continuous variables and REAP-S scores (total, ‘healthy foods’ and ‘avoidance of unhealthy foods’) were assessed using linear regression. Results: Overall, our sample had a mean REAP-S score of 27.6 (4.9), suggestive of a lower diet quality than the average general population in the US. There was a significant inverse relationship between mean REAP-S lower scores with increased BMI, waist circumference, disordered eating and depression. All these associations were significantly stronger in female participants. Limitations: EHR cross-sectional data. Conclusions: Our data suggest unhealthy diet quality in bipolar disorder is associated with depression, obesity and cardiometabolic abnormalities. Additional work is encouraged to prospectively track mood and diet quality to further understand the bidirectional relationship and clarify if dietary interventions can positively impact mood. Further delineating potential sex differences in diet quality and depression may provide greater appreciation of modifiable risk factors for future cardiometabolic burden.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 150-155 |
| Number of pages | 6 |
| Journal | Journal of Affective Disorders |
| Volume | 310 |
| DOIs | |
| State | Published - Aug 1 2022 |
Bibliographical note
Funding Information:This paper was presented virtually in part as a rapid oral presentation at the 23rd Annual Conference of the International Society for Bipolar Disorders. Manuel Gardea-Resendez reports receiving support from the Mayo Foundation during the conduct of the study. Mark Frye has received grant support from Assurex Health, Myriad, Pfizer, Mayo Foundation, NIMH, and NIAAA; has been a consultant to Janssen Global Services, LLC, Mitsubishi Tanabe Pharma Corporation, Myriad, Sunovion, and Teva Pharmaceuticals; has received CME/Travel Support/presentation from CME Outfitters Inc. and Sunovian; reports having financial interest /stock ownership/royalties in Cymia LLC. Francisco Romo-Nava receives grant support from the National Institute of Mental Health K23 Award (K23MH120503) and from a 2017 NARSAD Young Investigator Award from the Brain and Behavior Research Foundation; is the inventor on a U.S. Patent and Trademark Office patent # 10,857,356; and has received non-financial research support from Soterix Medical. Susan McElroy reports receiving personal fees for advisory boards and/or consultation from Allergan, Avanir, Idorsia, Mitsubishi Tanabe Pharma America, Myriad, Novo Nordisk, Opiant, Shire, Sunovion, and Takeda (Shire); receiving grant support from Azevan, Brainsway, Marriott Foundation, Medibio, Neurocrine, Novo Nordisk, Otsuka, and Sunovian; and receiving payments from Johnson & Johnson for being an inventor on US Patent 6 323 236 B2. Dr. Prieto has received grant support from National Agency for Research and Innovation (ANID Chile) awards: FONDECYT Regular 1181365 and FONDEF ID19I10116. No other disclosures are reported.
Funding Information:
This paper was presented virtually in part as a rapid oral presentation at the 23rd Annual Conference of the International Society for Bipolar Disorders. Manuel Gardea-Resendez reports receiving support from the Mayo Foundation during the conduct of the study. Mark Frye has received grant support from Assurex Health, Myriad, Pfizer, Mayo Foundation, NIMH, and NIAAA; has been a consultant to Janssen Global Services, LLC, Mitsubishi Tanabe Pharma Corporation, Myriad, Sunovion, and Teva Pharmaceuticals; has received CME/Travel Support/presentation from CME Outfitters Inc. and Sunovian; reports having financial interest /stock ownership/royalties in Cymia LLC. Francisco Romo-Nava receives grant support from the National Institute of Mental Health K23 Award ( K23MH120503 ) and from a 2017 NARSAD Young Investigator Award from the Brain and Behavior Research Foundation ; is the inventor on a U.S. Patent and Trademark Office patent # 10,857,356; and has received non-financial research support from Soterix Medical . Susan McElroy reports receiving personal fees for advisory boards and/or consultation from Allergan, Avanir, Idorsia, Mitsubishi Tanabe Pharma America, Myriad, Novo Nordisk, Opiant, Shire, Sunovion, and Takeda (Shire); receiving grant support from Azevan, Brainsway, Marriott Foundation, Medibio, Neurocrine, Novo Nordisk, Otsuka, and Sunovian; and receiving payments from Johnson & Johnson for being an inventor on US Patent 6 323 236 B2. Dr. Prieto has received grant support from National Agency for Research and Innovation (ANID Chile) awards: FONDECYT Regular 1181365 and FONDEF ID19I10116 . No other disclosures are reported.
Publisher Copyright:
© 2022
Keywords
- Bipolar depression
- Bipolar disorder
- Cardiometabolic markers
- Diet quality
- Obesity
